GlassScriptPhysician profile
Yen Le
NPI 1699166819
$9,159.01
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,550 · 2022: $4,122 · 2023: $3,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Travel and Lodging: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.48 |
| Travel and Lodging | $1,382.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,742.91 | 2023 | Infinity, Proclaim |
| Abbvie INC. | $987.60 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $790.90 | 2021-2023 | Austedo, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $676.63 | 2021-2023 | |
| Sk Life Science, INC. | $515.11 | 2021-2023 | Xcopri |
| Avanir Pharmaceuticals, INC. | $420.45 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $383.93 | 2021-2023 | Ongentys, Ingrezza |
| Acadia Pharmaceuticals INC | $266.26 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $255.09 | 2022 | |
| Grt US Holding, INC. | $232.16 | 2021-2022 | |
| Ucb, INC. | $201.61 | 2021-2023 | Briviact |
| Amneal Pharmaceuticals LLC | $184.92 | 2022-2023 | Rytary |
| Tanabe Pharma America, INC. | $175.20 | 2021-2023 | |
| Axsome Therapeutics, INC. | $153.96 | 2023 | Sunosi |
| Janssen Pharmaceuticals, INC | $147.01 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yen Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.